Evidence map›Paper›PMID 40950282›Full record

ArticleAmerican journal of translational research2025

FBXO22 regulates proliferation, migration, and invasion of esophageal cancer cells via the WNT/β-catenin signaling pathway.

Rui Zheng, Wangwang Xu, Li Ma, Jing Wang, Jia Ma, Chen Liu, Li Yu, Yuyun Li, Yingjie Zhang, Hui Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rui ZhengBengbu Medical College Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Wangwang XuBengbu Medical College Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Li MaDepartment of Clinical Laboratory, Fuyang People's Hospital Fuyang 236000, Anhui, China.
Jing WangBengbu Medical College Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University Bengbu 233030, Anhui, China.
Jia MaDepartment of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Chen LiuDepartment of Critical Care Medicine, First Affiliated Hospital of Bengbu Medical University Bengbu 233030, Anhui, China.
Li YuDepartment of Laboratory Medicine, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Yuyun LiDepartment of Laboratory Medicine, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Yingjie ZhangDepartment of Laboratory Medicine, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.
Hui XuDepartment of Laboratory Medicine, School of Laboratory Medicine, Bengbu Medical University Bengbu 233030, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesFBXO22, a member of the F-box family, plays a crucial role in cancer development and progression. However, its expression and biological functions in esophageal cancer (ESCA) remain poorly understood.

methodsIn this study, we investigated FBXO22 expression in ESCA cancer tissues using immunohistochemistry and Western blot analyses. Functional assays, including CCK-8, flow cytometry, Western blot, scratch healing, and Transwell migration and invasion assays, were employed to evaluate the effects of FBXO22 modulation on ESCA cell viability, apoptosis, migration, and invasion. Additionally, a nude mouse model was used to assess the impact of FBXO22 silencing on tumor growth.

resultsWe found that FBXO22 expression was upregulated in ESCA tissues compared to normal tissues. Silencing FBXO22 inhibited ESCA cell viability, migration and invasion while promoting apoptosis. Conversely, FBXO22 overexpression had the opposite effects. Mechanistically, FBXO22 was found to influence the WNT/β-catenin signaling pathway, and its silencing retarded tumor growth in vivo.

conclusionsOur findings highlight the critical role of FBXO22 in ESCA progression and suggest it as a potential therapeutic target for ESCA.

Indexed as

ESCCFBXO22tumorigenesisWntβ-catenin

Identifiers

PMID40950282
PMCPMC12432743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.